Cronos Australia Ltd. (VIT) AI Stock Analysis

• Market Cap: AU$45.70M
• Dividend Yield: N/A
• Average Volume (3M): 152.23K
• Price to Earnings (P/E): 12.8
• Beta (1Y): 1.64
• Revenue Growth: 0.13%
• EPS Growth: -12.90%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 46
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): <0.01
• Shares Outstanding: 662,254,900
• 10 Day Avg. Volume: 131,945
• 30 Day Avg. Volume: 152,234
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 62 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

The overall stock score is driven by strong financial growth and technical indicators showing moderate bullish momentum. However, the valuation and absence of dividend yield could be of concern for some investors. The company's ability to manage costs and improve cash flow will be key for future performance.

Cronos Australia Ltd. Business Overview & Revenue Model

Company Description

Cronos Australia Ltd. (VIT) is a company engaged in the production, distribution, and sale of medicinal cannabis products. The company operates within the pharmaceutical and wellness sectors, offering a range of cannabis-derived products aimed at improving health and well-being. Cronos Australia Ltd. focuses on leveraging scientific research and innovation to provide high-quality, reliable cannabis products for medical use.

How the Company Makes Money

Cronos Australia Ltd. generates revenue primarily through the sale of its medicinal cannabis products. The company's key revenue streams include the direct sale of cannabis oils, capsules, and other derivatives to medical practitioners and pharmacies. Additionally, Cronos Australia Ltd. may engage in strategic partnerships and collaborations with other pharmaceutical companies to expand its product offerings and market reach. These partnerships can enhance its distribution network and provide additional revenue through licensing agreements or joint ventures. Factors such as regulatory compliance, product quality, and market demand significantly influence the company's earnings.

Cronos Australia Ltd. Financial Statement Overview

Summary

Cronos Australia Ltd. demonstrates robust growth in revenue and maintains a strong balance sheet with prudent financial management. However, declines in profit margins and cash flow generation could pose future challenges.

Income Statement

Cronos Australia Ltd. has shown significant revenue growth over the years, particularly from 2021 to 2022, indicating strong market demand for its products. The Gross Profit Margin has been improving, suggesting better cost management. However, Net Profit Margin has recently decreased, pointing to increased operational costs or pricing pressures. The EBIT and EBITDA margins have weakened compared to previous years, indicating potential operational inefficiencies.

Balance Sheet

The company maintains a healthy equity position with an improving equity ratio, indicating financial stability. The Debt-to-Equity ratio is manageable, showing conservative leverage practices. Return on Equity has declined recently, reflecting on the reduced net income. Overall, the balance sheet remains strong with sufficient equity backing its operations.

Cash Flow

Free Cash Flow Growth Rate has been negative, signaling potential challenges in generating free cash flow. However, Operating Cash Flow remains strong relative to net income, suggesting operational efficiency. The Free Cash Flow to Net Income Ratio has declined, indicating less cash being converted into income, which could impact future liquidity if trends continue.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	123.87M	117.34M	66.99M	1.69M	123.85K
Gross Profit	34.22M	25.96M	25.43M	872.93K	116.79K
EBITDA	7.08M	20.85M	10.87M	-486.62K	-3.74M
Net Income	3.51M	13.81M	6.05M	-4.05M	-3.94M
Balance Sheet
Total Assets	71.28M	46.90M	42.87M	12.69M	16.23M
Cash, Cash Equivalents and Short-Term Investments	11.35M	18.85M	16.08M	9.47M	14.69M
Total Debt	11.02M	1.28M	5.06M	2.36M	2.21M
Total Liabilities	32.84M	11.99M	16.79M	3.47M	2.73M
Stockholders Equity	38.78M	34.98M	26.10M	9.30M	13.44M
Cash Flow
Free Cash Flow	6.21M	8.78M	13.13M	1.01M	-5.16M
Operating Cash Flow	7.00M	9.71M	13.50M	1.07M	-4.89M
Investing Cash Flow	-13.20M	-837.72K	2.00M	-160.69K	-515.91K
Financing Cash Flow	-1.30M	-6.10M	-1.50M	-262.03K	19.93M

Cronos Australia Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.07
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VIT, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 60.42 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VIT.

Cronos Australia Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	62 Neutral	AU$45.70M	12.78	7.64%	―	0.13%	-12.90%
Sector *	51 Neutral	$7.85B	-0.18	-40.01%	2.28%	22.97%	-2.05%
ELLXF	―	$2.70M	―	-21.29%	―	―	―
CNGGF	―	$5.11M	―	-164.01%	―	―	―
HDRPF	―	$4.72M	―		―	―	―
LGP	―	AU$39.63M	11.36	4.10%	―	―	―
AGH	41 Neutral	AU$18.60M	―	-218.38%	―	-14.30%	29.69%

Cronos Australia Ltd. Corporate Events

Vitura Health Issues Unquoted Equity Securities

Vitura Health Limited has announced the issuance of unquoted equity securities, including 12,814,845 unquoted options and 6,593,145 performance rights, effective from August 1, 2025. This move is likely aimed at enhancing the company’s capital structure and providing incentives for performance, which could have implications for its market positioning and stakeholder interests.

The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Limited Announces Cessation of Performance Rights

Vitura Health Limited has announced the cessation of 137,979 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could affect stakeholder perceptions regarding the company’s ability to meet its performance targets.

The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Expands with Acquisition of Heyday Medical Clinic

Vitura Health Limited, through its joint venture Flora Holdings Pty Ltd, has acquired the Heyday Medical Clinic, a respected medicinal cannabis clinic in Australia. This acquisition strengthens Flora’s clinical network, positioning it as a leader in holistic healthcare, and expands patient access to both face-to-face and telehealth consultations. The deal involves acquiring key assets of Heyday Medical, with Vitura contributing 50% of the acquisition cost. The transition will see Heyday’s clinical team continue under Flora, enhancing the joint venture’s capacity to deliver quality patient care.

The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Reports Positive Q3 FY2025 Momentum

Vitura Health Limited reported positive business momentum in Q3 FY2025, aligning with its Strategic Reset goals. The company saw successive revenue and EBITDA growth, driven by the integration of Candor Medical and Releaf Group, expansion of its Canview platform, and operational efficiencies. Despite slightly missing its annual revenue growth target, Vitura anticipates meeting its EBITDA margin and OPEX efficiency goals, setting a strong foundation for FY2026.